Cargando…

Pembrolizumab (and friends) in pediatric malignancies: should we consider Hodgkin lymphoma a world of its own?

Detalles Bibliográficos
Autores principales:	Algeri, Mattia, Locatelli, Franco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2020
Materias:	Editorial Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7576004/ https://www.ncbi.nlm.nih.gov/pubmed/33145331 http://dx.doi.org/10.21037/atm.2020.04.54

Ejemplares similares

Late relapses in Hodgkin lymphoma – should we search for the needle in the haystack?
por: El‐Galaly, Tarec Christoffer, et al.
Publicado: (2022)

Real-World Healthcare Resource Utilization in Patients with Classical Hodgkin Lymphoma Treated with Pembrolizumab and Nivolumab in the USA
por: Laliberté, François, et al.
Publicado: (2020)

Use of pembrolizumab with or without pomalidomide in HIV-associated non-Hodgkin’s lymphoma
por: Lurain, Kathryn, et al.
Publicado: (2021)

The Role of Allogeneic Hematopoietic Stem Cell Transplantation in Pediatric Leukemia
por: Algeri, Mattia, et al.
Publicado: (2021)

Very Delayed Acute Hepatitis after Pembrolizumab Therapy for Advanced Malignancy: How Long Should We Watch?
por: Phan, Timothy, et al.
Publicado: (2021)

Erythema nodosum: what should we consider about it?
por: Babamahmoudi, Farhang, et al.
Publicado: (2016)

NephroCheck: should we consider urine osmolality?
por: Noto, Alberto, et al.
Publicado: (2019)

The golden era of videolaryngoscopy: costs we should consider
por: Choi, Geun Joo
Publicado: (2022)

Successful pregnancy and fetal outcome following previous treatment with pembrolizumab for relapsed Hodgkin's lymphoma
por: Le‐Nguyen, Alexandre, et al.
Publicado: (2021)

Effectiveness and Safety of Pembrolizumab in Recurrent and Relapsed Classic Hodgkin Lymphoma: A Systematic Review
por: Hossain, Md Fahad, et al.
Publicado: (2023)

Quality-of-life analysis of pembrolizumab vs brentuximab vedotin for relapsed/refractory classical Hodgkin lymphoma
por: Zinzani, Pier Luigi, et al.
Publicado: (2022)

What We Should Consider for Full Densification when Sintering
por: Kang, Suk-Joong L.
Publicado: (2020)

Should We Consider Screening Spirometry in Individuals Who Are “Asymptomatic”?
por: Fortis, Spyridon
Publicado: (2022)

Malignant Lymphomas other than Hodgkins's Disease
por: Crowther, D.
Publicado: (1981)

Prolonged Remission by Pembrolizumab and Brentuximab-Vedotin Combination Therapy in Heavily-Pretreated Relapsed/Refractory Hodgkin’s Lymphoma
por: Yu, Tsung-Ying, et al.
Publicado: (2020)

Five-year follow-up of KEYNOTE-087: pembrolizumab monotherapy for relapsed/refractory classical Hodgkin lymphoma
por: Armand, Philippe, et al.
Publicado: (2023)

Novel Therapeutic Approaches to Familial HLH (Emapalumab in FHL)
por: Merli, Pietro, et al.
Publicado: (2020)

Post-hepatectomy liver failure: Should we consider venous outflow?
por: Lhuaire, Martin, et al.
Publicado: (2015)

Should we consider the infusion of lipid emulsion in the resuscitation of poisoned patients?
por: Cave, Grant, et al.
Publicado: (2014)

How Should We Consider New Theories of Chiari Malformation Pathogenesis?
por: Chou, Dean
Publicado: (2019)

Should We Consider the Cardiovascular System While Evaluating CKD-MBD?
por: Rroji, Merita, et al.
Publicado: (2020)

COVID 19: Should we consider universal screening in trauma patients?
por: Gopinathan, Nirmal Raj, et al.
Publicado: (2020)

ACC Advocacy: We Own the Problem, We Must Own the Solution
por: Jones, Samuel O., et al.
Publicado: (2020)

Comparison of Efficacy of Pembrolizumab between Epstein-Barr Virus‒Positive and ‒Negative Relapsed or Refractory Non-Hodgkin Lymphomas
por: Kim, Seok-Jin, et al.
Publicado: (2019)

Brentuximab Vedotin and Pembrolizumab Combination in Patients with Relapsed/Refractory Hodgkin Lymphoma: A Single-Centre Retrospective Analysis
por: Massaro, Fulvio, et al.
Publicado: (2022)

Sequential pembrolizumab and AVD are highly effective at any PD-L1 expression level in untreated Hodgkin lymphoma
por: Allen, Pamela B., et al.
Publicado: (2022)

Should Response-Adapted Therapy Now Be the Standard of Care for Advanced Hodgkin’s Lymphoma?
por: Johnson, Peter, et al.
Publicado: (2017)

Hodgkin's lymphoma in developing countries: can we go further?()
por: Gaiolla, Rafael Dezen
Publicado: (2017)

Should We Consider Cancers as Embryonic Diseases or as Consequences of Stem-Cell Deregulation?
por: Bastid, Jérémy, et al.
Publicado: (2008)

Should We Consider Alternatives to Universal Well-Child Behavioral-Developmental Screening?
por: Urkin, Jacob, et al.
Publicado: (2015)

Small cell bladder cancer: should we consider prophylactic cranial irradiation?
por: Morgan, Tara Nikonow, et al.
Publicado: (2019)

Why We Should Consider Evidence-Based Treatment Options for Truncal Acne
por: Stein Gold, Linda, et al.
Publicado: (2021)

From Chilblains (Pernio) to Coeliac Disease—Should We Still Consider It Random?
por: Mašić, Mario, et al.
Publicado: (2022)

Synchronous Double Malignant Tumors Consisting of Stomach and Hodgkin's Lymphoma with Collision between Gastric Adenocarcinoma and Hodgkin's Lymphoma in the Stomach
por: Yanagawa, Naoki, et al.
Publicado: (2012)

The development of a decision aid to support Hodgkin lymphoma survivors considering lung cancer screening
por: Broadbent, Rachel, et al.
Publicado: (2022)

Metachronous Dual Primary Malignancies of Carcinoma of the Tongue and Hodgkin's Lymphoma
por: Mate, Pooja Uttam, et al.
Publicado: (2018)

Should Radiology IT be Owned by the Chief Information Officer?
por: Channin, David S., et al.
Publicado: (2009)

What should we consider in mixed chimerism after hematopoietic stem cell transplantation?
por: Lim, Jihyang
Publicado: (2011)

Intensive care unit acquired muscle weakness: when should we consider rehabilitation?
por: Puthucheary, Zudin, et al.
Publicado: (2009)

Cost and value in healthcare professional's education: should we consider a monopsony model?
por: Walsh, Kieran
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_g2n8t7g6cik1u3143skkeo8hsc